The only 3 "Buys" in the ASX 10
Market concentration has re-emerged as a worry word for equities markets over the last few years, even if the current state of affairs isn't as bad as some may have you believe.
Right now, the top 10 companies in the ASX 200 account for just under 49% of the index's total market capitalisation, a tick above the long-term average of 48.6%, and well below the record 56.6% hit in 2013 during the post-GFC mining boom.
According to analysis by VanEck, when ASX market concentration has been above the long-run average, an equal weighting allocation outperformed over the following five years in 91 out of 91 instances.
Given how top-heavy the ASX remains, it's arguably no surprise that there's a perceived lack of value amongst its biggest names. In fact, of the ASX 200's top 10 stocks, only three are currently rated a Buy, according to Market Index's Broker Consensus tool.
You can see which stocks made the cut, and what the brokers are saying about them below.
| Stock | Rating | Price Target | Potential |
| Commonwealth Bank of Australia (CBA) | Strong Sell | $125.40 | -26.4% |
| BHP Group (BHP) | Hold | $61.58 | 13.2% |
| Westpac (WBC) | Sell | $33.86 | -9% |
| ANZ Group (ANZ) | Hold | $36.81 | -4.9% |
| National Australia Bank (NAB) | Hold | $38.20 | 3% |
| CSL Ltd (CSL) | Buy | $199.94 | 1.3% |
| Wesfarmers (WES) | Hold | $74.63 | -4.9% |
| Macquarie Group (MQG) | Buy | $265.67 | 15.3% |
| Goodman Group (GMG) | Buy | $32.12 | 11.1% |
1 - CSL Ltd (ASX: CSL)
It's been a wild ride for one of the ASX's long-standing bluechips. From a share price of $300 in late 2024, the company saw its value plummet over the next 18 months after posting its first annual loss since 1994, a 15% cut to its global workforce and the struggles of its kidney and iron-deficiency business CSL Vifor.
But today, as Centennial Asset Management's Matthew Kidman said recently, CSL has bounced back from what's been a historically bad run for the ASX healthcare stalwart.
"What we've seen globally is that healthcare has had a bit of a renaissance," he said. "Everyone's being defensive, and healthcare is a go-to place. CSL is benefiting from that. It's a global company, and its earnings are probably not going to fall off the edge of a cliff here."
Morgan Stanley retained its Overweight rating, even as CSL has hit its target price of $200 a share. UBS is also a Buy, with a price target of $225, citing the company's reaffirmed FY27 underlying NPAT growth guidance of 5% and the appointment of new CEO Deborah Waterhouse.
But Morgans has revised its Buy rating to a Hold after the CSL share price doubled from its June lows, citing a reversal in sentiment and multiple expansion as the reasons for the recovery, not an improved earnings outlook.
2 - Macquarie Group (ASX: MQG)
Macquarie Group has comfortably outperformed the Big Four banks over the last year, thanks to strong performance across many of its divisions, and the gains it has made in the mortgage lending space.
In its analysis, Ord Minnett cited Macquarie's strong 1H27 results, which saw net operating income up 10% to $9.57 billion, 2% ahead of consensus. Its commodities and global markets division also saw operating income jump 34% higher, with banking and financial services up 7%.
"While not particularly cheap, earnings momentum remains positive and MQG retains attractive exposure to structural themes including infrastructure, digitisation, and energy transition," it wrote.
Ord Minnett holds an Accumulate rating on MQG, with a price target of $255. Morgan Stanley also retained its Overweight rating, with a price target of $277.
The bank was also awarded a gold star by Atlas Funds Management's High Dive for increasing its interim dividend by 16%, after net profits rose 49%.
3 - Goodman Group (ASX: GMG)
Industrial property and infrastructure developer Goodman Group has found itself in the middle of the AI story thanks to its recently-acquired 9.9% stake in embattled data centre operator NextDC (ASX: NXT) alongside Digital Realty.
It was the latest high profile move in the company's pivot towards the data centre space, and as ETF Shares' David Tuckwell wrote for Livewire recently, could be the first step in its plan to acquire the company, a plan Goodman has denied.
On the broker side, the move was also received positively, with Morgan Stanley, Citi and UBS also retaining their Buy/Overweight ratings.
Citi rates GMG a Buy, with a price target of $40, but believes its recent position in NextDC is more likely to be a co-investment position than a takeover.
Outside the NextDC investment, UBS also suggested Goodman's disciplined strategy would start paying off in FY27/28 given costs were mostly locked in on its big projects and its exposure to data centre rent growth should support strong yields and earnings in the medium term.
1 topic
3 stocks mentioned